251577-09-0

251577-09-0 structure

Name: FTI-2148
Chemical Name: N-[(5-{[(1H-Imidazol-4-ylmethyl)amino]methyl}-2'-methyl-2-biphenylyl)carbonyl]-L-methionine
CAS Number: 251577-09-0
Molecular Formula: C₂₄H₂₈N₄O₃S
Molecular Weight: 452.569
Catalog: Signaling Pathways Metabolic Enzyme/Protease Farnesyl Transferase
Create Date: 2018-06-11 07:55:20
Modify Date: 2025-08-27 19:32:10
FTI-2148 is a RAS C-terminal mimetic dual farnesyl transferase (FT-1) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC50s of 1.4 nM and 1.7 μM for FT-1 and GGT-1, respectively[1].

Name	N-[(5-{[(1H-Imidazol-4-ylmethyl)amino]methyl}-2'-methyl-2-biphenylyl)carbonyl]-L-methionine
Synonyms	L-Methionine, N-[[5-[[(1H-imidazol-4-ylmethyl)amino]methyl]-2'-methyl[1,1'-biphenyl]-2-yl]carbonyl]- N-[(5-{[(1H-Imidazol-4-ylmethyl)amino]methyl}-2'-methyl-2-biphenylyl)carbonyl]-L-methionine N-[(5-{[(1H-imidazol-4-ylmethyl)amino]methyl}-2'-methylbiphenyl-2-yl)carbonyl]-L-methionine

Description	FTI-2148 is a RAS C-terminal mimetic dual farnesyl transferase (FT-1) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC50s of 1.4 nM and 1.7 μM for FT-1 and GGT-1, respectively[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Metabolic Enzyme/Protease >> Farnesyl Transferase
Target	IC50: 1.4 nM (FT-1); 1.7 μM (GGT-1)[1]
In Vitro	FTI-2148 (30 μM) inhibits the farnesylation of the exclusively farnesylated protein HDJ2 in all 3 RAS-transformed NIH3T3 cells. Western Blot Analysis[2] Cell Line: KRAS HRAS, and NRAS-transformed NIH3T3 cells Concentration: 30 μM Incubation Time: Result: Inhibited the prenylation of KRAS and NRAS.
In Vivo	FTI-2148 (subcutaneous injection; 100 mg/kg/day; 14 days) results in breast tumor regression in a ras transgenic mouse model[1]. FTI-2148 (subcutaneous injection; 100 mg/kg/day; 4 days) results in 85–88% inhibition of FTase with no inhibition of GGTase I enzymatic activity in breast tumors from mice in vivo settings[1]. Animal Model: Ras transgenic mouse model[1] Dosage: 100 mg/kg/day Administration: Subcutaneous injection; 100 mg/kg/day; 14 days Result: Induced regression by 87 ± 3% of mammary carcinomas in mice.
References	[1]. Sun J, et al. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.Cancer Res. 2003 Dec 15;63(24):8922-9. [2]. Sun J, et al. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res. 1999 Oct 1;59(19):4919-26. [3]. Kazi A, et al. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.Clin Cancer Res. 2019 Oct 1;25(19):5984-5996.

Density	1.3±0.1 g/cm3
Boiling Point	730.1±60.0 °C at 760 mmHg
Molecular Formula	C₂₄H₂₈N₄O₃S
Molecular Weight	452.569
Flash Point	395.4±32.9 °C
Exact Mass	452.188202
LogP	2.45
Vapour Pressure	0.0±2.5 mmHg at 25°C
Index of Refraction	1.626

Hazard Codes	Xi

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

251577-09-0	817586-01-9
1217471-51-6	180977-34-8
170006-72-1	1217447-06-7
344900-92-1	170006-73-2
928658-23-5	13700-81-7
2748190-26-1	2229645-34-3
1270445-07-2	2229384-68-1
2228596-73-2	132033-92-2
92108-40-2	2748249-71-8
327-22-0	13508-52-6